In a real-world setting, is there a correspondence of physician-led disease severity assessments with patient-reported disease severity and impact assessments in patients with moderate-to-severe plaque psoriasis treated with secukinumab? Dr. Mark Kirchhof and Dr. Jon Levy on the 36-month results from the PURE registry as presented at EADV 2021.
>> View the video [5 min 43 sec]
This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.
In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.